{"id":562044,"date":"2026-02-03T00:00:00","date_gmt":"2026-02-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2025-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-landscape-forecast-disease-landscape\/"},"modified":"2026-03-31T10:23:33","modified_gmt":"2026-03-31T10:23:33","slug":"dlsfon0006-2026-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-landscape-forecast-disease-landscape","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2026-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-landscape-forecast-disease-landscape\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The non-Hodgkin\u2019s lymphoma (<abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>) and chronic lymphocytic leukemia (<abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>) therapy market is rapidly evolving as novel agents provide alternatives to conventional chemoimmunotherapy regimens. This report focuses on the most common and commercially relevant B-cell <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>s: diffuse large B-cell lymphoma (<abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr>), mantle cell lymphoma (<abbr title=\"mantle cell lymphoma\">MCL<\/abbr>), follicular lymphoma (<abbr title=\"follicular lymphoma\">FL<\/abbr>), chronic lymphocytic leukemia (<abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>), and small lymphocytic lymphoma (<abbr title=\"small lymphocytic lymphoma\">SLL<\/abbr>). The <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies Breyanzi (<abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>), Kymriah (Novartis), Tecartus (Gilead), and Yescarta (Gilead) offer curative potential for all disease subtypes. Bispecific T-cell engagers (<abbr title=\"bispecific T-cell engager\">BiTE<\/abbr>s), such as Lunsumio (Roche), Epkinly \/ Tepkinly (Genmab \/ AbbVie), and Columvi (Roche), compete with the <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies and are experiencing uptake in the relapsed \/ refractory settings. Antibody drug conjugates (<abbr title=\"antibody drug conjugate\">ADC<\/abbr>s) are carving out a niche in the treatment of <abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr>; three <abbr title=\"antibody drug conjugate\">ADC<\/abbr>s are available: Polivy (Roche), Zynlonta (<abbr title=\"antibody drug conjugate\">ADC<\/abbr> Therapeutics), and Adcetris (Pfizer). The noncovalent <abbr title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitor Jaypirca (Eli Lilly) joins the covalent <abbr title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitors Brukinsa (BeiGene), Calquence (AstraZeneca), and Imbruvica (Johnson &#038; Johnson \/ AbbVie), thus enabling multiple lines of <abbr title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitor therapy for <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> \/ <abbr title=\"small lymphocytic lymphoma\">SLL<\/abbr> and <abbr title=\"mantle cell lymphoma\">MCL<\/abbr>. As these drug classes move into earlier lines of therapy, the treatment sequence is changing and fueling substantial growth of the <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> &#038; <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> therapy market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How big are the clinically and commercially relevant drug-treatable <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> &#038; <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> populations, and how will drug-treatment rates evolve over 2024-2034?<\/li>\n<li>What factors are driving growth in the <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> &#038; <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> market, and which drug class will dominate the treatment of these diseases in 2034?<\/li>\n<li>How will label expansions for <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies, <abbr title=\"bispecific T-cell engager\">BiTE<\/abbr>s, and <abbr title=\"Bruton\u2019s tyrosine kinase\">BTK<\/abbr> inhibitors into earlier lines of treatment impact the <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> &#038; <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> market?<\/li>\n<li>Which emerging therapies are the most promising for <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> &#038; <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>, and what is their potential uptake during the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Geographies:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan.<\/li>\n<li><strong>Primary research:<\/strong> Country-specific interviews with thought-leading hematologist-oncologists. Survey data collected for this and other Clarivate research.<\/li>\n<li><strong>Epidemiology:<\/strong> Diagnosed incidence of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> &#038; <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> by country; drug-treatable and drug-treated cases segmented by disease subtype and line of therapy.<\/li>\n<li><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> &#038; <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/li>\n<li><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies.<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-562044","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562044\/revisions"}],"predecessor-version":[{"id":575209,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562044\/revisions\/575209"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=562044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}